DAX24.853 ±-0,0%Est506.011 -0,4%MSCI World4.343 -0,1%Top 10 Crypto8,4100 -1,6%Nas22.727 -1,5%Bitcoin55.269 -2,0%Euro1,1864 -0,1%Öl67,38 -3,2%Gold4.940 -2,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens Energy ENER6Y Siemens 723610 Mercedes-Benz Group (ex Daimler) 710000 SAP 716460 Deutsche Telekom 555750 Rheinmetall 703000 NVIDIA 918422 BASF BASF11 Gerresheimer A0LD6E Lufthansa 823212 Amazon 906866 Microsoft 870747 Allianz 840400 Bayer BAY001 DroneShield A2DMAA
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX letztlich kaum bewegt -- US-Börsen rot -- Mercedes-Benz: Gewinneinbruch -- Siemens erhöht Ergebnisprognose -- TKMS, Deutsche Börse, DroneShield, Birkenstock, Micron, Palantir, Fastly im Fokus
Top News
So viel wäre eine Investition in USD Coin von vor 5 Jahren heute wert So viel wäre eine Investition in USD Coin von vor 5 Jahren heute wert
Solana: So lohnend wäre eine Investition von vor 3 Jahren gewesen Solana: So lohnend wäre eine Investition von vor 3 Jahren gewesen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Syndax Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
17,90 EUR -0,40 EUR -2,19 %
STU
21,35 USD -0,35 USD -1,61 %
BTT
Syndax Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.1,56 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2AFL6

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS87164F1057

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSNDX

Syndax Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
PR NewswireSyndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
PR NewswireSyndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
PR NewswireSyndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
PR NewswireSyndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
finanzen.netSyndax Pharmaceuticals stellte Quartalsergebnis zum abgelaufenen Jahresviertel vor
PR NewswireSyndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
PR NewswireSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
PR NewswireSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
PR NewswireSyndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
PR NewswireSyndax Announces Appointment of Steven Closter as Chief Commercial Officer
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finanzen.netSyndax Pharmaceuticals: Bilanzzahlen zum vergangenen Quartal
PR NewswireSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax Announces Participation at Two Upcoming Investor Conferences
PR NewswireSyndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Participation at Two Upcoming Investor Conferences
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireSyndax Highlights Recent Updates and Anticipated 2024 Milestones
PR NewswireSyndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting
PR NewswireSyndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials
PR NewswireSyndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting
PR NewswireSyndax Announces Participation at Stifel Healthcare Conference
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finanzen.netSyndax Pharmaceuticals präsentierte das Zahlenwerk zum abgelaufenen Jahresviertel
PR NewswireSyndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals News

Syndax Pharmaceuticals News: auf dieser Seite finden Sie alle Syndax Pharmaceuticals News und Nachrichten zur Syndax Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Syndax Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Syndax Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.